Cipher receives Health Canada approval of CIP-Fenofibrate
Cipher Pharmaceuticals Inc. announced that it has received final approval from Health Canada for
CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for CIP- ... more
Solvay finalizes agreement to buy Fournier Pharma
Solvay announced today that it has signed a final purchase agreement with the shareholders of Fournier Pharma for the acquisition of 100% of the company. Substantial social and regulatory procedures have been successfully completed worldwide. The transaction, which now only awaits approval ... more
Fournier Pharma and Xytis Pharmaceutcials sign licensing agreement for Anatibant
Fournier Pharma and Xytis Pharmaceuticals Ltd. announced that they have signed an agreement for the development and commercialisation of Anatibant (LF16-0687MS), a potential new medication for the treatment of traumatic brain injury, originating from Fournier Pharma's Research.
Fournier Ph ... more